Table 1

Effect of E/P and T/E/P treatment on the absolute count of peripheral lymphocytes over time

Cell populationTreatmentSlope
(cells/µL per week)*
P value
CD19+ B cellsE/P–3.20<0.001
T/E/P–1.050.118
Treatment–weeks interaction†2.150.020
Total (CD3+)
T cells
E/P1.110.813
T/E/P16.080.002
Treatment–weeks interaction†14.970.032
CD8+ T cellsE/P1.160.431
T/E/P6.99<0.001
Treatment–weeks interaction†5.830.007
CD4+ T cellsE/P0.990.727
T/E/P9.490.003
Treatment–weeks interaction†8.490.045
  • *Slope reflects the trend of absolute cell count over time as determined using a linear mixed-effects model.

  • †The treatment–weeks interaction between the slopes of the treatment groups (T/E/P vs E/P) was determined to evaluate the treatment effect of trilaciclib.

  • E/P, etoposide and carboplatin; T/E/P, trilaciclib prior to etoposide and carboplatin.